Market Access Preparing for the pharma fraud enforcement surge Here is what robust, risk-based compliance looks like in 2026.
Market Access Changing Faces: Boards of Directors and Advisory Boards, May... The latest Board moves reflect a focus on experience in commercialisation, corporate governance, and therapeutic development.
Market Access A dynamic moment for pharma pricing: Insights from PPIC At PPIC in Basel, pharma pricing experts discussed how policy changes and AI advances are altering the dynamics of pharmaceutical pricing and access.
Market Access Sponsored Company Profile: Acumetis Acumetis is a global expert commercialisation partner purposefully built to help life sciences companies win in the age of connectivity.
Market Access Why 70% of pharma partnership spend misses patients Finding a start-up or building an app is the cheap part; combining capabilities into something that scales across markets is the expensive part.
Market Access Industry exercises option for midpoint review of VPAG Invest... Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?
News UK's Mission divests kidney drug to Dimerix for $292m Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
